Kornimate/medical-research-clean huggingface dataset:
a study of acute kidney injury in children at sohag university hospital

Conditions: Acute Kidney Injury

Summary: acute kidney injury (aki) has been traditionally defined as an abrupt loss of kidney function leading to a rapid decline in the glomerular filtration rate (gfr), accumulation of waste products such as blood urea nitrogen (bun) and creatinine, and dysregulation of extracellular volume and electrolyte homeostasis . acute kidney injury (aki) is a very common condition, especially among hospitalized patients. this work aims to study the demographics, etiology, clinical characteristics, and outcome of acute kidney injury in children in sohag university hospital - pediatrics department.


Eligibility criteria:
inclusion criteria: * all children with acute kidney injury with an age range from 1 month to 16 years old exclusion criteria: 1. patients with chronic kidney disease (ckd) 2. patients with irregular follow up 3. patients with incomplete data 4. patients whose medical guardians refuse participation in the study
solid tumors in rasopathies

Conditions: RASopathy; Costello Syndrome; Cardio-Facio-Cutaneous Syndrome; Noonan Syndrome

Summary: rasopathies are a group of syndromes, caused by variants of genes involved in the regulation of the ras/map/erk pathway. this intracellular transduction pathway profoundly affects embryogenic development, organogenesis, synaptic plasticity and neuronal growth. rasopathies are characterized by multi-organ involvement, growth delay, premature aging and haemato-oncological manifestations. based on evidences provided by literature, cancer screening protocols are applied in some individuals affected by rasopathies, even though detailed information about prevalence and molecular pathogenesis of such tumors is still not clearly elucidate.

to define the prevalence of solid (non-haematological) neoplasms in a monocentric cohort of patients affected by rasopathies to perform next generation sequencing (ngs) analysis on tissue samples to preliminarily characterize the molecular pathogenesis of solid tumors in these patients' categories.

Eligibility criteria:
inclusion criteria: * clinical and molecularly confirmed diagnosis of a rasopathy exclusion criteria: * clinical diagnosis of rasopathy without molecular characterization
covid-19 igg antibodies in the serum of recovered patients

Conditions: Covid19

Summary: coronavirus disease 2019 (covid-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2), which first appeared in china, in december 2019 and is now spreading worldwide and poses a great threat to public health. in 12th july 2020, the total number of cases worldwide was about 13 million cases with case fatality rate of 4.4% and in egypt the total cases was 81158 and case fatality rate was 4.6%. (1,2). in recent years, novel coronaviruses emerge periodically in different areas around the world. severe acute respiratory syndrome coronavirus (sars-cov) occurred in 2002, which reportedly infected 8422 people with about 10% case fatality rate (3). middle east respiratory syndrome coronavirus (mers-cov) was first identified in 2012 in saudi arabia, bringing a total of 1401 mers-cov infections, and about 35% case fatality rate (1). all the infection cases and recent epidemics show that coronaviruses impose a continuous threat to human beings and the economy as they emerge unexpectedly, spread easily, and lead to catastrophic consequences. as the number of recovered patients with covid-19 continues to be increasing, the strength and duration of immunity after infection is an important point to be studied. moreover, understanding this issue is a critical point for controlling this epidemic as they are the key for herd immunity and for informing decisions on how and when to ease physical distancing restrictions and to be ready for other waves of the infection. there is currently no evidence if the people who have recovered from covid-19 have antibodies and protected from a second attack of infection or future wave of this pandemic or not. therefore, we will carry out a longitudinal study of immunity in recovered patients to assess sars-cov2 patients' risk for future reinfection.


Eligibility criteria:
inclusion criteria: * adults aged ≥ 20 years. * prior covid-19 infection confirmed by pcr detection of sars-cov-2 rna or antigen in nasopharyngeal swab. * recovery from infection either confirmed by two consecutive negative pcr (collected ≥24 hours apart) or passing of 14 days since onset of covid-19 symptoms and at least 3 days since resolution of fever without the use of antipyretics and improvement of respiratory symptoms exclusion criteria: * presence of any chronic illness interfere with immunity (autoimmune diseases). * pregnancy. * recovery from three months or more.
pharmacogenetic response to chemotherapy induction for orl cancers

Conditions: Carcinoma, Squamous Cell; Mouth Neoplasms; Oropharyngeal Neoplasms; Laryngeal Neoplasms; Hypopharyngeal Neoplasms

Summary: the purpose of this study is to determine if there is a correlation between tumor response after 3 doses of chemotherapy by induction using docetaxel, cisplatine and 5-fluorouracile for advanced stage epidermoid carcinomas of the upper aero digestive tract and the presence of one or a combination of 3 genetic polymorphisms and/or 5 intra-tumoral transcriptional modifications.


Eligibility criteria:
inclusion criteria: * squamous cell carcinoma originating in the mouth, oropharynx, larynx or hypopharynx has been histologically documented. * the disease is at one of the following uicc 2002 stages, regardless of ganglion status: t3 mo or t4 mo * treatment via chemotherapy, radiotherapy or surgery (except for the diagnostic biopsy) has not started * the pluridisciplinary committee as ruled out surgical options for technical or functional reasons * absence of distant metastases * oms general health status between 0 and 2 * patient has given informed consent * patient is affiliated with a social security system exclusion criteria: * undifferentiated squamous cell carcinomas in the nasopharynx (ucnt) * another cancer priorly treated with one of the following chemotherapies: docetaxel, cisplatin, 5-fluorouracile * creatininemia \> 2 mg/dl and/or creatinine clearance \< 60ml/min * patient under guardianship * presence of another severe pathology including: * severe or chronic cardiac, renal and/or hepatic insufficiencies * severe medullary hypoplasia * severe autoimmune disease * psychosis or senility
inflammatory markers in exhaled breath condensates from asthmatic patients

Conditions: Asthma

Summary: this study aims to compare the inflammatory mediators in exhaled breathe condensates from allergic and non-allergic asthmatic patients.


Eligibility criteria:
inclusion criteria: 1. have been diagnosed as asthma at least 6 months before enrolled to the study 2. known skin prick test results to aeroallergens ; either positive or negative 3. 15-65 years of age exclusion criteria: 1. on oral or inhaled corticosteroids within 1 month before the study 2. having asthma exacerbation 3. being pregnant 4. suffering from severe systemic disease/ in bad health

Keywords: asthma exhaled breath condensates cytokines
evaluation of velcade given as retreatment to multiple myeloma patients for efficacy, safety and tolerability

Conditions: Multiple Myeloma

Summary: multiple myeloma represents the second most common hematological malignancy.velcade is a small molecule to treat human malignancies. its anti-neoplastic effect invovles several distinct mechanisms including inhibition of cell growth. patients who have relapsed or are refractory to therapy, the standard of care is now velcade based on the results of previous clinical trials.


Eligibility criteria:
inclusion criteria: 1. voluntary written informed consent with the understanding that the consent may be w/d by the patient at any time w/o prejudice to future medical care. 2. patient previously diagnosed with multiple myeloma (mm). 3. patient previously tolerated 0.7, 1.0, or 1.3 mg/m2/dose of velcade alone or therapy combination and had at least a greater/equal 50% reduction in m-protein upon completion of velcade therapy. the dor prior to velcade greater/equal 4 months for the patient population. 4. it has been greater/equal 2 months since the patient's last velcade dose and the patient meets certain lab criteria as per protocol. 5. patient has a karnosfsky performance status greater/equal 60%. 6. patient has a life-expectancy greater than 3 months. 7. patient has laboratory values (defined in protocol) within 14 days before enrollment. exclusion criteria: 1. patients with a hx of pd, minimal response, or stable disease (sd)on first exposure to velcade. 2. patient has received chemotherapy, radiotherapy, immunotherapy or experimental therapy to treat multiple myeloma since their last dose of velcade. 3. patients who achieved a cr or pr but relapsed while on therapy. 4. patient had major surgery w/in 2 wks before enrollment. 5. patient has a hx of allergic reaction to compounds containing boron or mannitol. 6. patient has peripheral sensory neuropathy of grade 2 w/pain or greater intensity. 7. patient has cardiac amyloidosis. 8. patient has poorly controlled hypertension, diabetes mellitus, or other serious medical or pysychiatric illness. 9. patient is known to be human immunodeficiency virus (hiv)+. 10. patient is known to be hepatitis b surface antigen-positive or has known active hepatitis c infection. 11. patient has an active systemic infection requiring treatment. 12. female patient is pregnant or breast-feeding. confirmation must be established by a negative serum b-hcg. 13. patient is currently enrolled in another clinical research study.

Keywords: multiple myeloma retreatment velcade
self management and recovery training (smart) recovery study

Conditions: Alcohol Use Disorder

Summary: this study identifies whether and how online support groups may work to confer therapeutic benefits onto its participants.

online support groups (e.g., smart recovery) are an increasingly common non-professional intervention for people who engage in problematic alcohol use, but it is unclear how they help participants reduce their use. the primary objective of this study is to determine whether alcohol use decreases more after attending online smart recovery psychoeducational support group meetings, as compared to receiving psychoeducational content alone. the secondary objectives are to identify whether variables such as quality of life and recovery capital (i.e., resources to support recovery from addiction) relate to treatment outcomes.

Eligibility criteria:
inclusion criteria: * is fluent in english and have a 6th grade reading level or higher * audit score of ≥8 * has some desire to cut down or quit their alcohol use * has access to a phone or computer with reliable internet connection, a functional microphone and camera * is willing to consent to being audio and video recorded during the meetings exclusion criteria: * is not able to commit to the 6 weeks of intervention and the one- and three-month follow-up. * has vulnerable population status (e.g., pregnant people, prisoners)
durvalumab and tremelimumab in combination with first-line chemotherapy in advanced solid tumors

Conditions: Small Cell Lung Carcinoma; Carcinoma, Squamous Cell of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Esophagogastric Junction Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal Squamous Cell Carcinoma

Summary: durvalumab and tremelimumab in combination with first-line chemotherapy in the following indications: ovarian/peritoneal/fallopian tube cancer, scchn, tnbc, sclc and gastric/gej cancer, pdac, escc.

7 cohorts of first-line chemotherapy regimens combined with durvalumab + tremelimumab. this study will evaluate the safety and tolerability of durvalumab (medi4736) + tremelimumab in combination with first line chemotherapy regimens in patients with locally advanced or metastatic solid tumors: ovarian/peritoneal/fallopian tube cancer, squamous cell carcinoma of the head and neck (scchn), triple negative breast cancer (tnbc), small cell lung carcinoma (sclc), and gastric/gastro-esophageal junction (gej) cancer, pancreatic ductal adenocarcinoma (pdac) and esophageal squamous cell carcinoma (escc).

Eligibility criteria:
inclusion criteria: 1. ≥18 years 2. written informed consent 3. patients with histologically or cytologically documented chemotherapy-naïve locally advanced unresectable or metastatic ovarian/peritoneal/fallopian tube cancer, scchn, tnbc, sclc, gastric cancer/gej, pdac and escc. 4. ecog performance status of 0 or 1 5. patients must be considered suitable candidates for, and able to receive, first line chemotherapy for metastatic disease 6. at least 1 lesion, not previously irradiated, that can be accurately measured at baseline 7. no prior exposure to immune-mediated therapy 8. adequate organ and marrow function as defined below exclusion criteria: 1. receipt of any investigational anticancer therapy within 28 days or 5 halflives, whichever is longer, prior to the first dose of study treatment 2. brain metastases or spinal cord compression unless asymptomatic or treated and stable off steroids and anti-convulsants for at least 1 month prior to study treatment 3. any unresolved grade ≥2 toxicity from previous anticancer therapy 4. active or prior documented autoimmune or inflammatory disorders 5. uncontrolled intercurrent illness, including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring aes from study drugs, or compromise the ability of the patient to give written informed consent 6. mean qt interval corrected for heart rate using fridericia's formula (qtcf) ≥470 ms 20. active tuberculosis 7. active infection including tuberculosis, hepatitis b, hepatitis c, or human immunodeficiency virus (hiv)

Keywords: durvalumab, tremelimumab, metastatic, solid tumors, immuno-oncology, first-line chemotherapy, esophageal, pancreatic
effect of perioperative low dose ketamine on postoperative recovery in patients undergoing breast cancer surgery

Conditions: Breast Cancer

Summary: breast cancer patients often have perioperative emotional disorders such as anxiety and depression, which can lead to poor quality of recovery.this study aims to determine whether ketamine could improve the quality of recovery in breast cancer patients. meanwhile, it will show if ketamine could improve anxiety, depression, postoperative pain and fatigue.this trial also will bring great concerns on patients' mental health perioperatively and explore the measures to improve their quality of life.


Eligibility criteria:
inclusion criteria: 1. american society of anesthesiologists grade i-ii 2. patients undergoing elective breast cancer surgery under general anesthesia exclusion criteria: 1. unstable hypertension, history of heart disease 2. hepatic or renal dysfunction 3. patients undergoing chemotherapy before surgery 4. have a history of chronic pain or chronic use of analgesic 5. have mental illness or can't cooperate with investigators 6. have a history of ketamine allergy

Keywords: ketamine breast cancer surgery postoperative recovery
a clinical study of iepc intervent subjects with cerebral hemorrhagic stroke

Conditions: Stroke, Ischemic

Summary: this is a single centre、single arm、open-label，to investigate the safety and efficacy of epc transplantation in the brain

the purpose of this study is to evaluate the efficacy and safety of transplantation epcs intervent subjests with cerebral hemorrhagic stroke.

Eligibility criteria:
inclusion criteria: 1. subjects ≥ 18 and ≤ 80 years of age 2. subjects was confirmed cerebral hemorrhagic stroke, included at least one of risk factors(hypertension, diabetes, coronary heart disease, high blood lipid), and satisfied with one of the following conditions: a. significant stenosis (\> 50%) of the intracranial and extracranial arteries or their branches due to atherosclerosis, or clinical or imaging manifestations of vascular blockage b. head imaging (ct or mri) : cerebral hemispheric infarct lesion diameter of \> 1.5cm; or there were more than 2 discontinuous lesions in the blood supply area of the same intracranial external artery. c. auxiliary examination: color ultrasonography, cta, mra or dsa of the blood vessels in the neck confirmed that the intracranial or extracranial stenosis was greater than or equal to 50%； 3. serum creatinine ≤ 1.5 mg/dl ； serum alt/ast）≤2.5×uln；alb≥25g/l； 4. serum creatinine≤ 176.8umol/l（2.0 mg/dl）； 5. prothrombin time（pt）≤15s，international standardization rates（inr）\<1.7； 6. the glucose should be control between 2.8\~22.2mmol/l（50\~400mg/dl）； 7. adult patients were willing to use reliable contraceptives (such as condoms) and not to donate sperm throughout the study period and within three months of discharge 8. subjects and the guardians able to undergo post-physical therapy/rehabilitation exclusion criteria: 1. non-atherogenic cerebral infarction: cardiogenic embolization, small artery occlusion type is, other exact etiology is, and unknown etiology is 2. combined with cerebral hemorrhage or previous intracranial external blood history, arteriovenous malformation and aneurysm history, or prone to hemorrhage (platelet count below 100 x 109/l) 3. the vital signs of subjects are not stable 4. subjects with class iii/iv cardiovascular disability according to the new york heart association classification 5. at rest systolic pressure of 170mmhg or diastolic pressure of 105mmhg, or other indications of uncontrolled hypertension 6. subjects have one kinds of tumors within 5 years 7. the subject was suffering from neurological or mental illness 8. subjects had congenital or acquired immune deficiencies, active tuberculosis and other active infections (e.g., pulmonary infection, urinary tract infection, skin infection) 9. alcoholics 10. receipt of any investigational drug or device within 3 month 11. active hepatitis b (hbv dna\>1000copy/ml), hepatitis c or hiv infection 12. subjects who have other conditions that were not appropriate for the group determined by the researchers.
effectiveness of wearable trackers and telerehabilitation in cerebral palsy

Conditions: Cerebral Palsy (CP); Telerehabilitation; Physical Activity

Summary: the inadequate number of rehabilitation sessions and the difficulties in accessing rehabilitation services for people with cerebral palsy result in delayed progress and low levels of physical activity for these people. as a result, it is well known that daily life often hinders the implementation of prescribed home programmes, leading to neglect. in the rehabilitation of people with cerebral palsy, physiotherapists face difficulties in monitoring patients and ensuring compliance with home exercise programmes. both people with cerebral palsy and their carers often experience dissatisfaction and lack of motivation regarding the monitoring and control of development and activity. this study aims to evaluate the effectiveness of a telerehabilitation programme supported by a mobile application and a wearable activity tracker, in addition to a standard rehabilitation programme, on physical activity levels, quality of life, sleep quality, balance, activity participation and motivation, and patient satisfaction in people with cerebral palsy.


Eligibility criteria:
inclusion criteria: * aged between 14 and 18 years old * diagnosed with cerebral palsy * currently enrolled in a regular rehabilitation programme * level 1-3 according to gross motor function classification system (gmfcs) * no cognitive impairments affecting the understanding of exercise programmes * voluntary informed consent to participate * no recent surgeries (e.g. botox, muscle relaxation) within the past 6 months * no socioeconomic issues related to the use of smart devices exclusion criteria: * the impact of recent surgical procedures or medical interventions on physical performance. * the influence of health conditions that affect the entire body and physical performance.
cognitive behavioral therapy for treatment of pathological gambling

Conditions: Gambling

Summary: this study will determine the effectiveness and cost-effectiveness of three different treatment strategies in reducing gambling behaviors.

the number of pathological gamblers in the united states is steadily growing, leading to significant financial, psychological, and public health consequences. however, studies examining the effectiveness of treatment interventions for pathological gamblers are limited. this study will compare the effectiveness of three different treatment strategies, including referral to gambler's anonymous (ga), a self-help manual, and cognitive behavioral therapy (cbt), in reducing gambling behaviors and other problems related to pathological gambling. this study will last 8 weeks. participants will be randomly assigned to one of three interventions. group 1 participants will be referred to ga and 8 weeks of cbt, which focuses on teaching skills to help reduce gambling urges and develop alternative behaviors to gambling. group 2 participants will be referred to ga and given an 8-week self-help manual. group 3 participants will be referred to ga alone. questionnaires will be used to assess participants' gambling behavior and any personal, legal, or health problems they may be experiencing. the questionnaires will be completed at study entry, study completion, and at 6- and 12-month follow-up visits. participants will be asked to identify at least one person who knows about their gambling problem and will have regular contact with them during the study and for at least 1 year this person will be interviewed at the beginning of the study, and at months 2, 6 and 12. researchers will ask contact persons about participants' gambling behaviors, personal relationships, legal problems, use of health care and mental health services, and how the participant can be contacted if he or she moves. for information on related studies, please follow these links: http://clinicaltrials.gov/show/nct00118391 http://clinicaltrials.gov/show/nct00618462

Eligibility criteria:
inclusion criteria: * diagnosis of pathological gambling * 3 or more gambling episodes within 60 days prior to study entry exclusion criteria: * inability to read english at the 5th grade level * uncontrolled psychiatric condition

Keywords: pathological gambling gambler's anonymous cognitive behavioral therapy cbt